Dr. Gupta on Evolving Treatments for RCC

Shilpa Gupta, MD
Published: Wednesday, Sep 06, 2017



Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the CABOSUN trial investigating cabozantinib (Cabometyx) and sunitinib (Sutent) in patients with renal cell carcinoma (RCC). This was a small study that focused on intermediate- and poor-risk patients, states Gupta.

If sunitinib gets approved in the adjuvant setting, and with the positive findings for immunotherapy, the entire treatment landscape of RCC is currently in flux, Gupta says. There is hope for the combination of TKIs and immunotherapies, explains Gupta, such as the combination of nivolumab, ipilimumab, and cabozantinib.
 


Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the CABOSUN trial investigating cabozantinib (Cabometyx) and sunitinib (Sutent) in patients with renal cell carcinoma (RCC). This was a small study that focused on intermediate- and poor-risk patients, states Gupta.

If sunitinib gets approved in the adjuvant setting, and with the positive findings for immunotherapy, the entire treatment landscape of RCC is currently in flux, Gupta says. There is hope for the combination of TKIs and immunotherapies, explains Gupta, such as the combination of nivolumab, ipilimumab, and cabozantinib.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x